Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy
People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according ...
Feb 23, 2026
0
0









